ERBB2 and breast cancer: A real-world study involving 956 patients with HR+/HER2- breast cancer similarly identified 22.5% as a critical threshold, with patients exhibiting Ki67 ≥ 22.5% facing a higher risk of early recurrence and metastasis (39).